164 related articles for article (PubMed ID: 38461206)
21. De novo sirolimus-based immunosuppression after liver transplantation for hepatocellular carcinoma: long-term outcomes and side effects.
Toso C; Meeberg GA; Bigam DL; Oberholzer J; Shapiro AM; Gutfreund K; Ma MM; Mason AL; Wong WW; Bain VG; Kneteman NM
Transplantation; 2007 May; 83(9):1162-8. PubMed ID: 17496530
[TBL] [Abstract][Full Text] [Related]
22. Effects of maintenance immunosuppression with sirolimus after liver transplant for hepatocellular carcinoma.
Yanik EL; Chinnakotla S; Gustafson SK; Snyder JJ; Israni AK; Segev DL; Engels EA
Liver Transpl; 2016 May; 22(5):627-34. PubMed ID: 26784951
[TBL] [Abstract][Full Text] [Related]
23. Examinations of Factors Influencing Survival of Liver Transplantation for Hepatocellular Carcinoma: A Single-Center Experience From Budapest.
Piros L; Fehérvári I; Görög D; Nemes B; Szabó J; Gerlei Z; Végső G; Kóbori L; Máthé Z
Transplant Proc; 2015 Sep; 47(7):2201-6. PubMed ID: 26361680
[TBL] [Abstract][Full Text] [Related]
24. Impact of Pretransplant Bridging Locoregional Therapy for Patients With Hepatocellular Carcinoma Within Milan Criteria Undergoing Liver Transplantation: Analysis of 3601 Patients From the US Multicenter HCC Transplant Consortium.
Agopian VG; Harlander-Locke MP; Ruiz RM; Klintmalm GB; Senguttuvan S; Florman SS; Haydel B; Hoteit M; Levine MH; Lee DD; Taner CB; Verna EC; Halazun KJ; Abdelmessih R; Tevar AD; Humar A; Aucejo F; Chapman WC; Vachharajani N; Nguyen MH; Melcher ML; Nydam TL; Mobley C; Ghobrial RM; Amundsen B; Markmann JF; Langnas AN; Carney CA; Berumen J; Hemming AW; Sudan DL; Hong JC; Kim J; Zimmerman MA; Rana A; Kueht ML; Jones CM; Fishbein TM; Busuttil RW
Ann Surg; 2017 Sep; 266(3):525-535. PubMed ID: 28654545
[TBL] [Abstract][Full Text] [Related]
25. Clinical analysis of patients with hepatocellular carcinoma recurrence after living-donor liver transplantation.
Na GH; Hong TH; You YK; Kim DG
World J Gastroenterol; 2016 Jul; 22(25):5790-9. PubMed ID: 27433092
[TBL] [Abstract][Full Text] [Related]
26. Efficacy and safety of sirolimus early conversion protocol in liver transplant patients with hepatocellular carcinoma: A single-arm, multicenter, prospective study.
Su RY; Ling SB; Shan QN; Wei XY; Wang R; Jia CK; Zhuang L; Shen T; Ding LM; Xu ZD; Luo LB; Sun LB; Li GM; Fang TS; Jiang N; Zhang K; Su ZJ; Peng ZH; Lang R; Jiang T; He Q; Ye LS; Yang Y; He YT; Guo WZ; Lan LG; Sun XY; Chen D; Chen ZS; Zhou DW; Ye SJ; Ye QF; Tian M; Shi JH; Wang B; Liu J; Lu Q; Rao W; Cai JZ; Lv T; Yang JY; Wang PS; Zhong L; Ma JS; Li QG; Wu SD; Lu CJ; Lu CD; Zhang DH; Wang X; Li ZQ; Teng MJ; Li JJ; Jiang WT; Li JH; Zhang QB; Zhu NQ; Wang ZX; He K; Xia Q; Song SH; Fu ZR; Qiu W; Lv GY; Song RP; Wang JZ; Wang Z; Zhou J; Chen G; Zhao YP; Li L; Hu ZM; Luo QJ; Si ZZ; Xie B; He XS; Guo ZY; Zheng SS; Xu X
Hepatobiliary Pancreat Dis Int; 2022 Apr; 21(2):106-112. PubMed ID: 34583911
[TBL] [Abstract][Full Text] [Related]
27. Mammalian target of rapamycin inhibitors are associated with lower rates of hepatocellular carcinoma recurrence after liver transplantation: a systematic review.
Cholongitas E; Mamou C; Rodríguez-Castro KI; Burra P
Transpl Int; 2014 Oct; 27(10):1039-49. PubMed ID: 24943720
[TBL] [Abstract][Full Text] [Related]
28. Sirolimus-based immunosuppression improves outcomes in liver transplantation recipients with hepatocellular carcinoma beyond the Hangzhou criteria.
Ling S; Feng T; Zhan Q; Duan X; Jiang G; Shen T; Shan Q; Xu S; Ye Q; Liu P; Cen B; Zheng S; Xu X
Ann Transl Med; 2020 Feb; 8(4):80. PubMed ID: 32175373
[TBL] [Abstract][Full Text] [Related]
29. Sirolimus-based immunosuppression in liver transplantation for hepatocellular carcinoma: a meta-analysis.
Liang W; Wang D; Ling X; Kao AA; Kong Y; Shang Y; Guo Z; He X
Liver Transpl; 2012 Jan; 18(1):62-9. PubMed ID: 21964956
[TBL] [Abstract][Full Text] [Related]
30. Sirolimus and metformin synergistically inhibit hepatocellular carcinoma cell proliferation and improve long-term survival in patients with HCC related to hepatitis B virus induced cirrhosis after liver transplantation.
Shen C; Peng C; Shen B; Zhu Z; Xu N; Li T; Xie J
Oncotarget; 2016 Sep; 7(38):62647-62656. PubMed ID: 27577068
[TBL] [Abstract][Full Text] [Related]
31. Antitumor effect of sorafenib and mammalian target of rapamycin inhibitor in liver transplantation recipients with hepatocellular carcinoma recurrence.
Jung DH; Tak E; Hwang S; Song GW; Ahn CS; Kim KH; Moon DB; Ha TY; Park GC; Ryoo BY; Lee KJ; Kim N; Kwon JH; Jwa EK; Lee SG
Liver Transpl; 2018 Jul; 24(7):932-945. PubMed ID: 29710388
[TBL] [Abstract][Full Text] [Related]
32. Comparison of survival and tumor recurrence rates in patients undergoing liver transplantation for hepatitis B-related hepatocellular carcinoma using Milan, Shanghai Fudan and Hangzhou criteria.
Gao T; Xia Q; Qiu DK; Feng YY; Chi JC; Wang SY; Xi ZF; Zhang JJ; Xu N; Chen SY; Qiu YL; Shen LW; Zhou TT; Dong XJ; Li QG; Li H
J Dig Dis; 2013 Oct; 14(10):552-8. PubMed ID: 23782458
[TBL] [Abstract][Full Text] [Related]
33. Effect of different immunosuppressive schedules on recurrence-free survival after liver transplantation for hepatocellular carcinoma.
Vivarelli M; Dazzi A; Zanello M; Cucchetti A; Cescon M; Ravaioli M; Del Gaudio M; Lauro A; Grazi GL; Pinna AD
Transplantation; 2010 Jan; 89(2):227-31. PubMed ID: 20098287
[TBL] [Abstract][Full Text] [Related]
34. The Importance of the Immunosuppressive Regime on Hepatocellular Carcinoma Recurrence After Liver Transplantation.
Yilmaz S; Ince V
J Gastrointest Cancer; 2021 Dec; 52(4):1350-1355. PubMed ID: 34611833
[TBL] [Abstract][Full Text] [Related]
35. Time of hepatocellular carcinoma recurrence after liver resection and alpha-fetoprotein are important prognostic factors for salvage liver transplantation.
Lee S; Hyuck David Kwon C; Man Kim J; Joh JW; Woon Paik S; Kim BW; Wang HJ; Lee KW; Suh KS; Lee SK
Liver Transpl; 2014 Sep; 20(9):1057-63. PubMed ID: 24862741
[TBL] [Abstract][Full Text] [Related]
36. Sirolimus improves the prognosis of liver recipients with hepatocellular carcinoma: A single-center experience.
Liu P; Wang X; Liu H; Wang SX; Xu QG; Wang L; Xu X; Cai JZ
Hepatobiliary Pancreat Dis Int; 2023 Feb; 22(1):34-40. PubMed ID: 36513566
[TBL] [Abstract][Full Text] [Related]
37. Efficacy and safety of combination therapy with everolimus and sorafenib for recurrence of hepatocellular carcinoma after liver transplantation.
De Simone P; Crocetti L; Pezzati D; Bargellini I; Ghinolfi D; Carrai P; Leonardi G; Della Pina C; Cioni D; Pollina L; Campani D; Bartolozzi C; Lencioni R; Filipponi F
Transplant Proc; 2014; 46(1):241-4. PubMed ID: 24507059
[TBL] [Abstract][Full Text] [Related]
38. Alpha-fetoprotein level > 1000 ng/mL as an exclusion criterion for liver transplantation in patients with hepatocellular carcinoma meeting the Milan criteria.
Hameed B; Mehta N; Sapisochin G; Roberts JP; Yao FY
Liver Transpl; 2014 Aug; 20(8):945-51. PubMed ID: 24797281
[TBL] [Abstract][Full Text] [Related]
39. [Factors for predicting outcomes of liver transplantation and liver resection for hepatocellular carcinoma meeting Milan criteria].
Huang J; Zhou J
Nan Fang Yi Ke Da Xue Xue Bao; 2014 Mar; 34(3):406-9. PubMed ID: 24670459
[TBL] [Abstract][Full Text] [Related]
40. Experience With Early Sorafenib Treatment With mTOR Inhibitors in Hepatocellular Carcinoma Recurring After Liver Transplantation.
Invernizzi F; Iavarone M; Zavaglia C; Mazza S; Maggi U; Cesarini L; Antonelli B; Airoldi A; Manini MA; Sangiovanni A; Rossi G; Donato MF; Saverio Belli L; Lampertico P
Transplantation; 2020 Mar; 104(3):568-574. PubMed ID: 31517781
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]